Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a ...
The AMPLIFY trial introduced AVO as a new standard for untreated CLL patients with wild-type TP53, excluding high-risk TP53 aberration cases. A phase II study evaluated AVO in high-risk CLL patients, showing 42% CR with BM-uMRD rates and 71% BM-uMRD rates in TP53 aberration patients. AVO was well-tolerated, with low-grade toxicities, supporting its use as a standard treatment for high-risk CLL.
Related Clinical Trials
Reference News
The AMPLIFY trial introduced AVO as a new standard for untreated CLL patients with wild-type TP53, excluding high-risk TP53 aberration cases. A phase II study evaluated AVO in high-risk CLL patients, showing 42% CR with BM-uMRD rates and 71% BM-uMRD rates in TP53 aberration patients. AVO was well-tolerated, with low-grade toxicities, supporting its use as a standard treatment for high-risk CLL.